Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson’s disease
ROT-TDS - with shown BE to the originator reference product - displayed similar safety and local tolerability as the reference product in patients with PD. The results show a trend to improved skin adhesion of the new patch compared to the reference in the target population.
Authors
- Annika Dax
- Wolfgang H. Jost (ORCID: https://orcid.org/0000-0002-8574-3297)
- Barbara Schug (ORCID: https://orcid.org/0000-0001-8137-6509)
- Ana Leblanc (ORCID: https://orcid.org/0000-0002-0446-8239)
- Björn Schurad (ORCID: https://orcid.org/0000-0001-6101-5247)
- Ralph‐Steven Wedemeyer
- Maggie Haitian Wang (ORCID: https://orcid.org/0000-0003-1223-4595)
- Gabriel Wauer
- André Warnke
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2024-10-07
- DOI
- https://doi.org/10.5414/cp204672
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.74